The adjuvant effects of co-stimulatory molecules on cellular and memory responses to HBsAg DNA vaccination
✍ Scribed by Xiaogang Du; Guoxing Zheng; Huali Jin; Youmin Kang; Junpeng Wang; Chong Xiao; Shuo Zhang; Lin Zhao; Aoshuang Chen; Bin Wang
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 852 KB
- Volume
- 9
- Category
- Article
- ISSN
- 1099-498X
- DOI
- 10.1002/jgm.1004
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Because DNA vaccines on their own tend to induce weak immune responses in humans, adjuvant methods are needed in order to improve their efficacy. The co‐stimulatory molecules 4‐1BBL, OX40L, and CD70 have been shown to induce strong T cell activities; therefore, in this study, we investigated whether they may be used as molecular adjuvants for a hepatitis B surface antigen (HBsAg) DNA vaccine (pcDS2) in eliciting strong cellular and memory responses. Compared to mice immunized with pcDS2 alone, addition of the co‐stimulatory molecules increased T cell proliferation and an HBsAg‐specific antibody response that was marked with a higher ratio of IgG2a/IgG1. Importantly, pcDS2 plus these co‐stimulatory molecules elicited a higher level of IFN‐γ and IL‐4 in CD4^+^ T cells and a higher level of IFN‐γ in CD8^+^ T cells. In addition, a significantly robust antigen‐specific cytotoxic T lymphocyte (CTL) response and the production of long‐term memory CD8^+^ T cells were also observed in the groups immunized with pcDS2 plus 4‐1BBL, OX40L, or CD70. Consistently, as late as 100 days after immunization, upregulated expressions of BCL‐2, Spi2A, IL‐7Ra, and IL‐15Ra were still observed in mice immunized with pcDS2 plus these co‐stimulatory molecules, suggesting the generation of memory T cells in these groups. Together, these results suggest that the co‐stimulatory molecules 4‐1BBL, OX40L, or CD70 can enhance the immunogenicity of HBsAg DNA vaccines, resulting in strong humoral, cellular, and memory responses. This approach may lead to an effective therapeutic vaccine for chronic hepatitis B virus (HBV) infection. Copyright © 2007 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
## Abstract Immunologic adjuvants are used to augment the immunogenicity of MHC class I–restricted peptide vaccines, but this effect has rarely been systematically evaluated in a clinical trial. We have investigated, in a phase I study, whether addition of the 2 adjuvants GM‐CSF and KLH can enhance